Technical Bulletins

INOmax DS Technical Bulletins:	Download
INOmax DS Software Version 1.4.0	TB 0040
INOmax DS use with Bunnell Life Pulse	TB 0041
INOmax DS and Percussionaire Bronchotron	TB 07005
INOmax DS-Bunnell Life Pulse Low Flow-Low Dose Conditions	TB 07006
INOmax DS and Cannula Low Flow Delivery	TB 07007
INOmax DS and Volume Ventilation of Neonate	TB 08001
INOmax DS Testing Standard	TB 08003
INOmax DS-INOblender Use of Cleaning Agents	TB 08004
INOvent and Respironics BiPap Vision	TB 08005
INOblender use with Nebulizers	TB 08006
INOmax DS Ventilator Compatibility List	TB 08007
INOmax DS Non Invasive Applications	TB 08008
Ventilator Applications	TB 09001
Coaxial Anesthesia circuits not recommended for use with the INOmax DS	TB 09002
Ventilator Applications	TB 09003

The product information provided in this site is intended only for residents of the United States.
The product discussed herein may have different product labeling in different countries.

INOMAX^® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

INOMAX Important Safety Information

INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Therefore, methemoglobin levels should be monitored during INOMAX administration. Caution should be used when administering INOMAX with other drugs that can cause methemoglobinemia regardless of their route of administration
Nitrogen dioxide (NO₂) forms rapidly in gas mixtures containing nitric oxide and oxygen. NO₂ formed in this way can cause airway inflammation and damage
INOMAX must be administered through a system that does not cause excessive generation of NO₂ and that monitors for NO, NO₂, and FiO₂
Abrupt discontinuation of INOMAX therapy can lead to worsening of PaO₂ and increasing pulmonary artery pressure (PAP). Deterioration in oxygenation and elevation in PAP can also occur in children with no apparent response to INOMAX
In patients with pre-existing left ventricular dysfunction, inhaled nitric oxide may increase pulmonary capillary wedge pressure leading to pulmonary edema

Please see Full Prescribing Information.

Refer a Colleague to INOMAX^®

Disclaimer

*Please note: When you access these resources, you are leaving the INOMAX website. Therefore, INOMAX and Ikaria Holdings Inc. do not endorse the accuracy of the information you may find. We encourage you to talk to your doctor about the accuracy of any information you discover through these Internet resources.

Agree and continue →

Technical Bulletins

Refer a Colleague to INOMAX®

Get INOMAX® Email Updates

Disclaimer

Refer a Colleague to INOMAX^®

Get INOMAX^® Email Updates